Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 33 Days Sales Outstanding is 73.00 as of Mar. 2026, which is 10% below its 10-year median of 80.84. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €17.26. The stock has 6 warning signs investors should review. Among 836 Biotechnology companies, VivoSim Labs ranks worse than 63.04% on this metric.
VivoSim Labs's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.03 Mil. VivoSim Labs's Revenue for the
three
months ended in Mar. 2026 was €0.04 Mil.
Hence, VivoSim Labs's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 73.00.
The historical rank and industry rank for VivoSim Labs's Days Sales Outstanding or its related term are showing as below:
FRA:4OR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.09 Med: 80.84 Max: 309.75
Current: 88.6
During the past 13 years, VivoSim Labs's highest Days Sales Outstanding was 309.75. The lowest was 39.09. And the median was 80.84.
FRA:4OR's Days Sales Outstanding is ranked worse than 63.04% of 836
companies
in the Biotechnology industry
Industry Median: 68.89
vs FRA:4OR: 88.60
VivoSim Labs's Days Sales Outstanding
increased
from Mar. 2025 (51.45) to Mar. 2026 (73.00).
VivoSim Labs (FRA:4OR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
VivoSim Labs Days Sales Outstanding Related Terms
VivoSim Labs Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Days Sales Outstanding Comparison
For the Biotechnology subindustry, VivoSim Labs's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Days Sales Outstanding of 73.00 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on VivoSim Labs and its competitors. This is 10% below median its historical median of 80.84. Over the past decade, VivoSim Labs' Days Sales Outstanding has ranged from 39.09 to 309.75. According to the industry distribution chart, VivoSim Labs ranks #527 out of 836 companies in the Biotechnology industry, placing it in the top 63%.
Is VivoSim Labs' Days Sales Outstanding too high?
VivoSim Labs' current Days Sales Outstanding of 73.00 is 10% below median its 10-year median of 80.84. Over the past 10 years, this metric has ranged from a low of 39.09 to a high of 309.75. The Biotechnology industry median Days Sales Outstanding is 68.89. VivoSim Labs' value of 73.00 is 6% above this industry median. Based on the distribution chart, VivoSim Labs ranks #527 out of 836 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Days Sales Outstanding compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #527 out of 836 companies for Days Sales Outstanding. This places VivoSim Labs in the lower half of its industry. The industry median Days Sales Outstanding is 68.89. VivoSim Labs' value of 73.00 is 6% above this benchmark. Historically, VivoSim Labs' own Days Sales Outstanding has ranged from 39.09 to 309.75 over the past decade. While the company's 10-year median is 80.84 vs. the industry median of 68.89, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.89, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Days Sales Outstanding of 73.00 is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Days Sales Outstanding is 73.00, which is 10% below median its own 10-year median of 80.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Days Sales Outstanding of 73.00. The stock's GF Value™ is €17.26, compared to a current price of €3.49 — trading 79.8% below its estimated fair value. The current Days Sales Outstanding is 73.00, which is 10% below median its 10-year median of 80.84 and 6% above the Biotechnology industry median of 68.89. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Days Sales Outstanding is 73.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 79.8% below its estimated GF Value™ of €17.26.
Key valuation signals for FRA:4OR:
Days Sales Outstanding: 73.00 (10% below median its 10-year median of 80.84)
GF Value™: €17.26 vs. price of €3.49 (79.8% below fair value)
Industry Position: 6% above the Biotechnology median (#527 of 836)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
